Haneen Shalabi

3.8k total citations · 1 hit paper
47 papers, 866 citations indexed

About

Haneen Shalabi is a scholar working on Oncology, Public Health, Environmental and Occupational Health and Electrical and Electronic Engineering. According to data from OpenAlex, Haneen Shalabi has authored 47 papers receiving a total of 866 indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Oncology, 12 papers in Public Health, Environmental and Occupational Health and 9 papers in Electrical and Electronic Engineering. Recurrent topics in Haneen Shalabi's work include CAR-T cell therapy research (41 papers), Acute Lymphoblastic Leukemia research (12 papers) and Virus-based gene therapy research (7 papers). Haneen Shalabi is often cited by papers focused on CAR-T cell therapy research (41 papers), Acute Lymphoblastic Leukemia research (12 papers) and Virus-based gene therapy research (7 papers). Haneen Shalabi collaborates with scholars based in United States, United Kingdom and Egypt. Haneen Shalabi's co-authors include Nirali N. Shah, Bonnie Yates, Terry J. Fry, Cindy Delbrook, Maryalice Stetler‐Stevenson, Constance M. Yuan, Daniel W. Lee, Crystal L. Mackall, Pamela L. Wolters and Staci Martin and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Haneen Shalabi

40 papers receiving 862 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL

2021 200 citations Nirali N. Shah, Daniel W. Lee et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Haneen Shalabi United States	15	777	222	184	172	167	47	866
Sandhya Sharma United States	10	641 0.8×	261 1.2×	118 0.6×	251 1.5×	49 0.3×	21	735
Corinne Summers United States	15	1.3k 1.7×	411 1.9×	343 1.9×	319 1.9×	253 1.5×	42	1.5k
Huiwen Jiang China	11	367 0.5×	105 0.5×	102 0.6×	135 0.8×	62 0.4×	27	533
Evandro D. Bezerra United States	9	393 0.5×	95 0.4×	87 0.5×	80 0.5×	89 0.5×	31	523
Xia Mao China	16	512 0.7×	123 0.6×	104 0.6×	235 1.4×	79 0.5×	66	741
Xue Lin United States	6	441 0.6×	120 0.5×	147 0.8×	160 0.9×	62 0.4×	10	516
Aimee C. Talleur United States	13	399 0.5×	100 0.5×	85 0.5×	117 0.7×	47 0.3×	47	583
Fenlu Zhu United States	9	485 0.6×	125 0.6×	197 1.1×	186 1.1×	95 0.6×	21	593
Hejin Jia China	7	706 0.9×	196 0.9×	220 1.2×	202 1.2×	87 0.5×	11	784
Chunrong Tong China	11	337 0.4×	86 0.4×	69 0.4×	108 0.6×	61 0.4×	50	450

Countries citing papers authored by Haneen Shalabi

Since Specialization

Citations

This map shows the geographic impact of Haneen Shalabi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haneen Shalabi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haneen Shalabi more than expected).

Fields of papers citing papers by Haneen Shalabi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Haneen Shalabi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haneen Shalabi. The network helps show where Haneen Shalabi may publish in the future.

Co-authorship network of co-authors of Haneen Shalabi

This figure shows the co-authorship network connecting the top 25 collaborators of Haneen Shalabi. A scholar is included among the top collaborators of Haneen Shalabi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Haneen Shalabi. Haneen Shalabi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Valtis, Yannis K., Surabhi B Vora, Joseph M. Rocco, et al.. (2025). Pre-infusion risk factors predict severe infectious complications of CAR T-cell therapy in pediatric and adult patients with B-ALL. Journal for ImmunoTherapy of Cancer. 13(9). e012436–e012436.

Dreyzin, Alexandra, Bonnie Yates, Haneen Shalabi, et al.. (2025). Ten-year experience of CD22 CAR T cells for children and young adults with B-cell acute lymphoblastic leukemia. Blood Advances. 10(5). 1700–1712.

Silbert, Sara, Kai Rejeski, Keith Wilson, et al.. (2024). Development of ALL-Hematotox: predicting post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia. Blood. 145(11). 1136–1148. 5 indexed citations

Steineck, Angela, Sara Silbert, Kelly J. Shipman, et al.. (2024). Weathering the storm when the end of the road is near: A qualitative analysis of supportive care needs during CAR T‐cell therapy in pediatrics. Pediatric Blood & Cancer. 71(9). e31092–e31092. 4 indexed citations

Harb, Roa, et al.. (2024). Diagnostic pitfalls in assessment of ferritin following CAR‐T‐cell therapy: Understanding the hook effect. Pediatric Blood & Cancer. 71(9). e31171–e31171.

Yates, Bonnie, Seth M. Steinberg, Constance M. Yuan, et al.. (2023). Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell Failure. Transplantation and Cellular Therapy. 29(9). 574.e1–574.e10. 4 indexed citations

Silbert, Sara, Sanna Madan, Seth M. Steinberg, et al.. (2023). A comprehensive analysis of adverse events in the first 30 days of phase 1 pediatric CAR T-cell trials. Blood Advances. 7(18). 5566–5578. 2 indexed citations

Shalabi, Haneen, et al.. (2023). Intrathecal hydrocortisone for treatment of children and young adults with CAR T‐cell immune‐effector cell‐associated neurotoxicity syndrome. Pediatric Blood & Cancer. 71(1). e30741–e30741. 11 indexed citations

Molina, John C., Ting Zhou, Constance M. Yuan, et al.. (2022). Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation. Journal for ImmunoTherapy of Cancer. 10(5). e004483–e004483. 31 indexed citations

10.

Dreyzin, Alexandra, Sandhya R. Panch, Haneen Shalabi, et al.. (2022). Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells. Molecular Therapy — Methods & Clinical Development. 28. 51–61. 9 indexed citations

11.

Ligon, John A., Seth M. Steinberg, Toni Foley, et al.. (2022). The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes. Blood Advances. 6(23). 6040–6050. 25 indexed citations

12.

Shalabi, Haneen, Staci Martin, Bonnie Yates, et al.. (2022). Neurotoxicity following CD19/CD28ζ CAR T-cells in children and young adults with B-cell malignancies. Neuro-Oncology. 24(9). 1584–1597. 20 indexed citations

13.

Shalabi, Haneen, Anandani Nellan, Nirali N. Shah, & Juliane Gust. (2022). Immunotherapy Associated Neurotoxicity in Pediatric Oncology. Frontiers in Oncology. 12. 836452–836452. 11 indexed citations

14.

Molina, John C., Seth M. Steinberg, Bonnie Yates, et al.. (2021). Factors Impacting Overall and Event-Free Survival following Post-Chimeric Antigen Receptor T Cell Consolidative Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy. 28(1). 31.e1–31.e9. 12 indexed citations

15.

Yates, Bonnie, Alexander Ling, Constance M. Yuan, et al.. (2021). Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy. Blood Advances. 6(7). 2167–2182. 35 indexed citations

16.

Masih, Katherine E., John A. Ligon, Bonnie Yates, et al.. (2021). Consequences of hemophagocytic lymphohistiocytosis‐like cytokine release syndrome toxicities and concurrent bacteremia. Pediatric Blood & Cancer. 68(10). e29247–e29247. 10 indexed citations

17.

Shah, Nirali N., Daniel W. Lee, Bonnie Yates, et al.. (2021). Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL. Journal of Clinical Oncology. 39(15). 1650–1659. 200 indexed citations breakdown →

18.

Gonzalez, Corina, Elliot Levy, Vladimir Valera, et al.. (2021). Case Report: Fatal Complications of BK Virus-Hemorrhagic Cystitis and Severe Cytokine Release Syndrome Following BK Virus-Specific T-Cells. Frontiers in Immunology. 12. 801281–801281. 16 indexed citations

19.

Ligon, John A., Mukil Natarajan, Haneen Shalabi, et al.. (2019). Invasive fusariosis masquerading as extramedullary disease in rapidly progressive acute lymphoblastic leukemia. Pediatric Blood & Cancer. 66(7). e27732–e27732.

20.

Shalabi, Haneen, Cindy Delbrook, Maryalice Stetler‐Stevenson, et al.. (2018). Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Can Render Patients with ALL Into PCR-Negative Remission and Can be an Effective Bridge to Transplant (HCT). Biology of Blood and Marrow Transplantation. 24(3). S25–S26. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact